An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Prothena to Participate in Stifel 2023 Virtual CNS Days
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Prothena Corporation plc (NASDAQ: PRTA) will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023, at 10:30 AM ET. The event will be accessible via a live webcast through the company's investor relations section at www.prothena.com. After the live presentation, a replay of the webcast will be available for at least 90 days.
Prothena specializes in investigating therapeutics for neurodegenerative diseases and has a diverse pipeline targeting conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases.
Positive
None.
Negative
None.
DUBLIN, Ireland--(BUSINESS WIRE)--
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday March 28, 2023 at 10:30 AM ET.
A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
